The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

The 9 Truths About Hepatitis C Treatment Success

Back to News Homepage

Possible 8-Week Cure for Patients with Hepatitis C

February 15, 2017

Print this page

Learn more about a new, investigational Hepatitis C drug that has been granted priority review by the FDA. It is meant to help patients without cirrhosis and who are new to treatment.
Possible 8-Week Cure for Patients with Hepatitis C

Investigational Hepatitis C Drug Granted Priority Review

By Jennifer Barrett

The FDA has accepted AbbVie’s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P). The treatment is being evaluated for its ability to treat all major genotypes (GT1-6) of chronic hepatitis C virus (HCV).

The NDA is based on data from 8 studies which evaluated more than 2300 patients in 27 countries across all major HCV genotypes and special populations.

Continue reading this entire article:
http://www.pharmacytimes.com/product-news/investigational-hepatitis-c-drug-granted-priority-review

No Comments - be the first!
Share
Share

Previous

The 9 Truths About Hepatitis C Treatment Success

Back to News Homepage

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.